9th Annual Biomarkers Congress
HCV Drug Discovery
Hilton San Diego Resort

San Diego, California
http://www.drugdiscoverychemistry.com/
   Speakers
   --------

   N/A

   It is an exciting time for the field of HCV antivirals. Viral protease
   and polymerase inhibitors are in late stage clinical trials, as are
   combinations of them, suggesting an interferon-free drug cocktail to
   treat HCV may one day be possible. Progress is also being made on
   small molecule drug candidates that inhibit host proteins involved in
   the maturation/processing of HCV particles.

Schedule of Presentations:

Wednesday, April 28, 2010
12:30:00 Registration
13:25:00 Inhibiting HCV Polymerase (NS5B)
13:30:00 Chairperson's Opening Remarks
13:40:00 Structure-Based Design of Non-Nucleoside NS5B Inhibitors for the Treatment of HCV Francisco Talamas
14:10:00 PSI-7851: Development of a Nucleotide Prodrug for the Treatment of HCV Michael J. Sofia
14:40:00 Novel Phosphoramidate HCV NS5b Inhibitors Joseph M Patti
15:10:00 Sponsored Presentations (Opportunity Available)
15:40:00 Networking Refreshment Break, Poster and Exhibit Viewing
16:15:00 Inhibiting HCV NS5A
16:20:00 The Identification and Optimization of HCV Replicon Inhibitors Characterised by NS5A Specific Mutations Stuart Cockerill
16:50:00 Discovery and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Broad-Spectrum Coverage of all HCV Genotypes Richard Colonno
17:20:00 Break-Out Discussions
18:30:00 End of Day
Thursday, April 29, 2010
07:30:00 Breakfast Workshop Presentation (Sponsorship Opportunity Available) or Morning Coffee
08:10:00 Inhibiting HCV Protease
08:15:00 Chairperson's Opening Remarks
08:20:00 KEYNOTE Telaprevir: Discovery, Homologues and Clinical Update Youssef Bennani
09:00:00 Protein Silencing of Hepatitis C Virus NS3/4A Protease in vitro and in vivo With AVL-181 Juswinder Singh
09:30:00 Recent Developments in HCV NS3/4A Protease Inhibitor Nigel Liverton
10:00:00 Networking Coffee Break, Poster and Exhibit Viewing
10:45:00 Boron and Non-Boron-Based HCV NS3/4 Protease InIhibitors: Discovery of a Novel Motif Possessing High Potency against PI-Resistant Mutants Wieslaw Kazmierski
11:15:00 HCV-Protease Inhibitors: Current and the Next Generation Atul Agarwal
11:45:00 TMC435 Clinical Update and In Vitro Combination Kenny Simmen
12:15:00 Sponsored Presentation (Opportunity Available)
12:30:00 Walk and Talk Luncheon in the Exhibit Hall (Last Chance for Poster and Exhibit Viewing)
13:50:00 New Viral Targets
13:55:00 Chairperson's Remarks
14:00:00 Discovery of Potent and Mechanistically Distinct Inhibitors of HCV Entry William C. Olson
14:30:00 Core Protein: A New Target for the Development of Novel Small Molecule Inhibitors of HCV A. Donny Strosberg
15:00:00 Networking Refreshment Break
15:15:00 Targeting The Host
15:20:00 Development of SR-B1 Modulators as HCV Entry Inhibitors Jeffrey McKelvy
15:50:00 Targeting TLR7 James Appleman
16:20:00 Mechanism of HCV Resistance to Cyclophilin Inhibitors Hengli Tang
16:50:00 End of Conference
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.